Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., . . . Roberts, A. W. (2017). Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study. Lancet Oncol.
Chicago-stil citatSeymour, John F., et al. "Venetoclax Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukaemia: A Phase 1b Study." Lancet Oncol 2017.
MLA-referensSeymour, John F., et al. "Venetoclax Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukaemia: A Phase 1b Study." Lancet Oncol 2017.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.